GBP111.26
2.11% today
London, Apr 02, 10:45 am CET
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

AstraZeneca Target price 2025 - Analyst rating & recommendation

AstraZeneca Classifications & Recommendation:

Buy
85%
Hold
15%

AstraZeneca Price Target

Target Price GBP137.60
Price GBP113.66
Potential 21.06%
Number of Estimates 26
26 Analysts have issued a price target AstraZeneca 2026 . The average AstraZeneca target price is GBP137.60. This is 21.06% higher than the current stock price. The highest price target is GBP189.67 66.88% , the lowest is GBP105.46 7.22% .
A rating was issued by 33 analysts: 28 Analysts recommend AstraZeneca to buy, 5 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the AstraZeneca stock has an average upside potential 2026 of 21.06% . Most analysts recommend the AstraZeneca stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029


Dec '24 2025
Estimates
Revenue Billion GBP 42.32 44.44
14.82% 5.01%
EBITDA Margin 33.02% 34.43%
5.44% 4.28%
Net Margin 13.01% 16.91%
0.05% 30.00%

24 Analysts have issued a sales forecast AstraZeneca 2025 . The average AstraZeneca sales estimate is GBP44.4b . This is 5.03% higher than the revenue of the last 12 months(TTM). The highest sales forecast is GBP46.2b 9.14% , the lowest is GBP41.4b 2.06% .

This results in the following potential growth metrics:

Revenue Estimates

2024 GBP42.3b 14.82%
2025 GBP44.4b 5.01%
2026 GBP47.4b 6.64%
2027 GBP50.3b 6.14%
2028 GBP53.2b 5.79%
2029 GBP55.9b 5.07%

18 Analysts have issued an AstraZeneca EBITDA forecast 2025. The average AstraZeneca EBITDA estimate is GBP15.3b . This is 11.14% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is GBP18.3b 33.17% , the lowest is GBP12.8b 7.02% .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 GBP14.0b 21.08%
2025 GBP15.3b 9.50%
2026 GBP17.1b 11.74%
2027 GBP19.0b 10.96%
2028 GBP20.1b 6.03%
2029 GBP24.1b 19.76%

EBITDA Margin

2024 33.02% 5.44%
2025 34.43% 4.28%
2026 36.08% 4.79%
2027 37.72% 4.55%
2028 37.80% 0.21%
2029 43.09% 13.99%

16 AstraZeneca Analysts have issued a net profit forecast 2025. The average AstraZeneca net profit estimate is GBP7.5b . This is 36.14% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is GBP8.5b 53.41% , the lowest is GBP4.9b 10.82% .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 GBP5.5b 14.89%
2025 GBP7.5b 36.52%
2026 GBP9.1b 21.24%
2027 GBP10.3b 13.21%
2028 GBP11.6b 12.02%
2029 GBP14.3b 23.47%

Net Margin

2024 13.01% 0.05%
2025 16.91% 30.00%
2026 19.23% 13.72%
2027 20.51% 6.66%
2028 21.72% 5.90%
2029 25.52% 17.50%

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029


Dec '24 2025
Estimates
Earnings Per Share GBP 3.55 4.85
14.89% 36.62%
P/E 23.45
EV/Sales 4.41

16 Analysts have issued a AstraZeneca forecast for earnings per share. The average AstraZeneca EPS is GBP4.85 . This is 36.24% higher than earnings per share in the financial year 2024. The highest EPS forecast is GBP5.46 53.37% , the lowest is GBP3.17 10.96% .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 GBP3.55 14.89%
2025 GBP4.85 36.62%
2026 GBP5.88 21.24%
2027 GBP6.65 13.10%
2028 GBP7.45 12.03%
2029 GBP9.20 23.49%

P/E ratio

Current 31.94 7.42%
2025 23.45 26.58%
2026 19.34 17.53%
2027 17.09 11.63%
2028 15.25 10.77%
2029 12.35 19.02%

Based on analysts' sales estimates for 2025, the AstraZeneca stock is valued at an EV/Sales of 4.41 and an P/S ratio of 3.97 .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.63 7.03%
2025 4.41 4.74%
2026 4.14 6.22%
2027 3.90 5.79%
2028 3.68 5.47%
2029 3.51 4.83%

P/S ratio

Current 4.17 7.27%
2025 3.97 4.79%
2026 3.72 6.22%
2027 3.50 5.79%
2028 3.31 5.47%
2029 3.15 4.83%

Current AstraZeneca Upgrades & Downgrades

Analyst Rating Action Date
Berenberg Bank
Buy
Unchanged Mar 26 2025
Shore Capital
Buy
Unchanged Mar 07 2025
JP Morgan Cazenove
Overweight
Unchanged Feb 19 2025
Berenberg Bank
Buy
Unchanged Jan 27 2025
Berenberg Bank
Buy
Unchanged Jan 06 2025
JP Morgan Cazenove
Overweight
Unchanged Nov 22 2024
JP Morgan Cazenove
Overweight
Unchanged Nov 07 2024
Analyst Rating Date
Unchanged
Berenberg Bank:
Buy
Mar 26 2025
Unchanged
Shore Capital:
Buy
Mar 07 2025
Unchanged
JP Morgan Cazenove:
Overweight
Feb 19 2025
Unchanged
Berenberg Bank:
Buy
Jan 27 2025
Unchanged
Berenberg Bank:
Buy
Jan 06 2025
Unchanged
JP Morgan Cazenove:
Overweight
Nov 22 2024
Unchanged
JP Morgan Cazenove:
Overweight
Nov 07 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today